SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development
Base period provides $18.5 million to advance oral and IV SCY-247 into a Phase 2 trial for invasive candidiasis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.